// App-Quantinova.ai

CTNI-68 : FIREFLY-1 (PNOC026): PHASE 2 STUDY OF PAN-RAF INHIBITOR TOVORAFENIB IN PEDIATRIC AND YOUNG ADULT PATIENTS WITH RAF-ALTERED RECURRENT OR PROGRESSIVE LOW-GRADE GLIOMA OR ADVANCED SOLID TUMORS

Researchers

Presenter

  • Lindsay Kilburn

Principal Investigators

  • Sarah Leary

  • David Ziegler

  • Patricia Baxter

  • Andrea Franson

  • Geoffrey McCowage

  • Angela Waanders

  • Jasper Van der Lugt

  • Michal Yalon Oren

  • Nicolas Gerber

  • Nicholas Gottardo

  • Dong-Anh Khuong-Quang

  • Karsten Nysom

  • Simon Bailey

  • Pablo Hernaiz Driever

  • Sebastien Perreault

  • Olaf Witt

  • Seungmin Hahn

  • Darren Hargrave

  • Timothy Hassall

  • Nada Jabado

  • Hyoung Jin Kang

  • Valerie Larouche

  • Helen Toledano

  • Cassie Kline

  • Mohamed Abdelbaki

  • Susan Chi

  • Sharon Gardner

  • Nicholas Whipple

  • Sabine Mueller

  • Samuel Blackman

  • Xin Zhao

  • Daniel Da Costa

  • Michael Cox

  • Roger Packer

  • Jordan Hansford

Medical Centers

  • Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands

  • Sydney Children’s Hospitals Network, Westmead, New South Wales, Australia

  • Children’s Hospital of Philadelphia (CHOP), Philadelphia, PA, USA

  • Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA

  • Schneider Children's Medical Center of Israel, Petah Tikva, Israel

  • Day One Biopharmaceuticals, South San Francisco, CA, USA

  • Cancer and Blood Disorders Center, Seattle Children’s, Seattle, WA, USA

  • Perth Children’s Hospital, Nedlands, Australia

  • UCL Great Ormond Street Institute of Child Health, London, United Kingdom

  • Hopp Children’s Cancer Center Heidelberg (KiTZ), Heidelberg, Germany

  • Kids Cancer Centre, Sydney Children’s Hospital, Sydney, Australia

  • Children’s Cancer Centre, Royal Children’s Hospital, Victoria, Australia

  • Ann and Robert H. Lurie Children’s Hospital, Chicago, IL, USA

  • Washington University School of Medicine, St. Louis, MO

  • Seoul National University College of Medicine, Seoul National University Cancer Research Institute, Wide River Institute of Immunology, Seoul National University Children’s Hospital, Seoul, Republic of Korea

  • Sheba Medical Center, Tel Hashomer, Israel

  • Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität, Berlin, Germany

  • Texas Children’s Cancer Center, Texas Children’s Hospital, Baylor College of Medicine, Houston, TX, USA

  • C. S. Mott Children’s Hospital, University of Michigan, Ann Arbor, MI, USA

  • Centre Hospitalier Universitaire de Québec-Université Laval, Quebec City, Canada

  • University Childrens Hospital, Zurich, Switzerland

  • Dana-Farber Boston Children's Cancer and Blood Disorders Center, Boston, MA, USA

  • University of Utah, Salt Lake City, UT, USA

  • Duke University Medical Center, Durham, NC, USA

  • Children’s National Medical Center, Washington, DC, USA

  • Queensland Children’s Hospital, Brisbane, Australia

  • Northern Institute for Cancer Research, Newcastle University, Newcastle-upon-Tyne, United Kingdom

  • Juliane Marie Centre, Rigshospitalet, Copenhagen, Denmark

  • McGill University Health Centre, Montreal, QC, Canada

  • Michael Rice Cancer Centre, Women’s and Children’s Hospital; South Australia Health and Medical Research Institute; South Australian Immunogenomics Cancer Institute, University of Adelaide, Victoria, Australia

  • CHU Sainte-Justine, Université de Montréal, Montreal, Canada

  • Severance hospital, Yonsei University, Seoul, Republic of Korea

  • NYU Langone Medical Center, New York, NY, USA

Locations

  • Netherlands

  • United States

  • Australia

  • Canada

  • Switzerland

  • Israel

  • United Kingdom

  • Germany

  • Denmark

  • Republic of South Korea

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Genetic Disorder

Disease

  • Solid malignancies

  • Low-grade gliomas

  • Gliomas

  • Acro–dermato–ungual–lacrimal–tooth (ADULT) syndrome

Biomarkers

  • B-Raf proto-oncogene, serine/threonine kinase

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • Multicenteric

Phase

  • II

Study Id's

  • NCT04775485

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved